This page shows the latest eteplirsen news and features for those working in and with pharma, biotech and healthcare.
Vyondys 53 is Sarepta’s second approved DMD therapy after Exondys 51 (eteplirsen).
It is the company’s second DMD drug after Exondys 51 (eteplirsen), the first disease-modifying treatment for the disease to be introduced in the US.
Exondys 51 (eteplirsen), which was approved three years ago and made around $287m in sales in the first nine months of the year.
Vyondys 53 (golodirsen) is Sarepta’s second approved DMD therapy after Exondys 51 (eteplirsen), the first disease-modifying treatment to be introduced in the US for the inherited muscle-wasting disease
At the moment that includes already-market drugs that skip over or ignore the mutation in the dystrophin gene – such as PTC Therapeutics’ Translarna (ataluren) and Sarepta’s Exondys 51 (eteplirsen) –
Sarepta setback. There was bitter news from the CHMP for Sarepta, as the panel turned down its application for Duchenne muscular dystrophy drug Exondys (eteplirsen) for a second time, setting up ... Eteplirsen was approved in the US as Exondys 51 in 2016,
More from news
Approximately 3 fully matching, plus 23 partially matching documents found.
We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...